b5media.com

Advertise with us

Enjoying this blog? Check out the rest of the Business Channel Subscribe to this Feed

Health Care Insiders

August 16th, 2008

Gyms tailor offerings to cancer patients

While the data about exercise helping reduce risk of cancer has been out for a while, the idea that exercise can help during cancer treatment is gaining more and more traction. In fact, some gyms are tailoring their offerings specifically to people living with cancer and experiencing effects of treatment such as lymphedema and cancer-related […]

By Jen -- 0 comments

July 31st, 2008

FDA orders Amgen to revise labels on growth factors

The Food and Drug Administration has ordered pharmaceutical giant Amgen to revise labels on its growth factor products, which stimulate the production of blood cells and are used in patients with low blood counts undergoing treatment for diseases such as kidney disease and cancer. Some data released in the past year has shown that these […]

By Jen -- 0 comments

July 30th, 2008

WHYY Radio discusses high cost of chemo

As a researcher and strategist in oncology, I’m always excited to hear topics that I discuss every day come up on the news for public discussion. Last night was one example when I heard this fantastic segment on WHYY radio as part of the Radio Times program about the high cost of chemotherapy drugs. (Audio […]

By Jen -- 0 comments

July 8th, 2008

Doctors, as well as patients, stung by high cancer drug prices

The WSJ reports that patients aren’t the only ones stung by pricesfor Avastin and other expensive cancer drugs. Physicians are also getting burnt. While most drugs are prescribed directly to patients and picked up at a pharmacy, leaving the patient and/or insurance company with the bill (and the pharmacy with the overhead), most cancer drugs […]

By Jen -- 2 comments

July 7th, 2008

How much to pay for a drug that slows cancer, but doesn’t prolong life?

The NYT reported this weekend on something that’s been bugging all of us in the oncology world for quite some time. How much should we pay for drugs that seem to slow down cancer’s advance, but that don’t prolong the life of a patient? Some of these drugs lengthen “progression free survival” or other markers […]

By Jen -- 0 comments